[go: up one dir, main page]

IL163642A0 - Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative - Google Patents

Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

Info

Publication number
IL163642A0
IL163642A0 IL16364203A IL16364203A IL163642A0 IL 163642 A0 IL163642 A0 IL 163642A0 IL 16364203 A IL16364203 A IL 16364203A IL 16364203 A IL16364203 A IL 16364203A IL 163642 A0 IL163642 A0 IL 163642A0
Authority
IL
Israel
Prior art keywords
iressa
water
pharmaceutical formulation
cellulose derivative
soluble cellulose
Prior art date
Application number
IL16364203A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL163642(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL163642A0 publication Critical patent/IL163642A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16364203A 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative IL163642A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition
PCT/GB2003/000803 WO2003072139A1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

Publications (1)

Publication Number Publication Date
IL163642A0 true IL163642A0 (en) 2005-12-18

Family

ID=27767732

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16364203A IL163642A0 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
IL163642A IL163642A (en) 2002-02-26 2004-08-19 Irsa's pharmaceutical preparation contains a water-soluble cellulose derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163642A IL163642A (en) 2002-02-26 2004-08-19 Irsa's pharmaceutical preparation contains a water-soluble cellulose derivative

Country Status (30)

Country Link
US (2) US20050163835A1 (pl)
EP (1) EP1480679B1 (pl)
JP (1) JP4544863B2 (pl)
KR (2) KR20100090726A (pl)
CN (1) CN1326569C (pl)
AR (1) AR038848A1 (pl)
AT (1) ATE362771T1 (pl)
AU (1) AU2003208444B2 (pl)
BR (1) BRPI0307786B8 (pl)
CA (1) CA2476587C (pl)
CO (1) CO5601038A2 (pl)
CY (1) CY1108026T1 (pl)
DE (1) DE60313956T2 (pl)
DK (1) DK1480679T3 (pl)
ES (1) ES2286406T3 (pl)
HK (1) HK1070585A1 (pl)
IL (2) IL163642A0 (pl)
IS (1) IS2462B (pl)
MX (1) MXPA04008307A (pl)
MY (1) MY135609A (pl)
NO (1) NO328658B1 (pl)
NZ (1) NZ534513A (pl)
PL (1) PL208114B1 (pl)
PT (1) PT1480679E (pl)
RU (1) RU2318518C2 (pl)
SA (1) SA03240043B1 (pl)
TW (1) TWI271193B (pl)
UA (1) UA76325C2 (pl)
UY (1) UY27682A1 (pl)
WO (1) WO2003072139A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332322D1 (de) 2002-02-26 2010-06-10 Astrazeneca Ab Neue kristalline formen der krebsbekämpfenden verbindung zd1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
BRPI0510604B8 (pt) 2004-05-06 2021-05-25 Warner Lambert Co composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende
RU2424805C2 (ru) 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Стабильные фармацевтические композиции, включающие пиримидинсульфамид
EP3954715A3 (en) 2006-10-27 2022-05-04 Capsugel Belgium NV Hydroxypropyl methyl cellulose hard capsules and process of manufacture
US10406105B2 (en) * 2007-06-06 2019-09-10 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
KR20120046216A (ko) * 2009-07-02 2012-05-09 와이어쓰 엘엘씨 3-시아노퀴놀린 정제 제형 및 이의 용도
JP5779591B2 (ja) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Ａｂｔ−２６３カプセル剤
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
US20120277210A1 (en) 2010-10-29 2012-11-01 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20120129853A1 (en) 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis induction agent
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
US20180000827A1 (en) * 2014-12-19 2018-01-04 Synthon B.V. Pharmaceutical composition comprising gefitinib
FI4233847T3 (fi) * 2015-02-26 2024-09-24 Takeda Pharmaceuticals Co Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
CA2164344C (en) * 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
NZ510991A (en) * 1997-03-05 2002-11-26 Sugen Inc Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
DE60332322D1 (de) * 2002-02-26 2010-06-10 Astrazeneca Ab Neue kristalline formen der krebsbekämpfenden verbindung zd1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
JP4544863B2 (ja) 2010-09-15
KR20100090726A (ko) 2010-08-16
RU2004129280A (ru) 2005-06-10
KR20040088524A (ko) 2004-10-16
CY1108026T1 (el) 2013-09-04
BR0307786A (pt) 2004-12-07
IL163642A (en) 2007-07-24
ATE362771T1 (de) 2007-06-15
ES2286406T3 (es) 2007-12-01
DE60313956D1 (de) 2007-07-05
US20050163835A1 (en) 2005-07-28
CN1638805A (zh) 2005-07-13
TWI271193B (en) 2007-01-21
BRPI0307786B1 (pt) 2018-03-13
IS7420A (is) 2004-08-24
NO328658B1 (no) 2010-04-19
SA03240043B1 (ar) 2007-05-06
CO5601038A2 (es) 2006-01-31
HK1070585A1 (en) 2005-06-24
UY27682A1 (es) 2003-10-31
WO2003072139A1 (en) 2003-09-04
DK1480679T3 (da) 2007-09-03
EP1480679A1 (en) 2004-12-01
CA2476587C (en) 2010-05-04
KR101002374B1 (ko) 2010-12-17
TW200304379A (en) 2003-10-01
NO20043866L (no) 2004-09-15
BRPI0307786B8 (pt) 2021-05-25
AU2003208444A1 (en) 2003-09-09
US20090186890A1 (en) 2009-07-23
PL208114B1 (pl) 2011-03-31
AR038848A1 (es) 2005-01-26
UA76325C2 (uk) 2006-07-17
DE60313956T2 (de) 2008-05-15
CA2476587A1 (en) 2003-09-04
NZ534513A (en) 2007-04-27
PT1480679E (pt) 2007-07-18
EP1480679B1 (en) 2007-05-23
MY135609A (en) 2008-05-30
IS2462B (is) 2008-11-15
RU2318518C2 (ru) 2008-03-10
AU2003208444B2 (en) 2006-10-26
PL372215A1 (pl) 2005-07-11
MXPA04008307A (es) 2004-11-26
JP2005523293A (ja) 2005-08-04
CN1326569C (zh) 2007-07-18

Similar Documents

Publication Publication Date Title
IL163642A0 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
TWI349664B (en) Benzimidazole derivatives: preparation and pharmaceutical applications
AU2002350719A1 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
IL221199A (en) A fragrance-containing drug
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
IL161623A (en) Nicotin-or isonicotin benzothiazole derivatives, their preparation and pharmaceutical compositions comprising them
AU2003901813A0 (en) Pharmaceutical derivatives
TWI319317B (en) Modified release pharmaceutical formulation
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
AU2003276572A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
IL165069A0 (en) Immediate release pharmaceutical formulation
SI1673349T1 (sl) Derivati benzimidazola: priprava in farmacevtske uporabe
IL166098A0 (en) 3-guanindinocarbonyl-1-heteroaryl-indole derivatives preparation process their use as medicaments and pharmaceutical compositions comprising them
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
AU2002346457A1 (en) Pharmaceutical formulations comprising indolinone derivatives
PL374761A1 (pl) Pochodne N-benzodioksolilo, N-benzodioksanylo i N-benzodioksepinylo arylokarboksyamidu oraz kompozycje farmaceutyczne, zawierające takie pochodne
AU2003245033A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
AU2003280387A1 (en) Pharmaceutical formulation comprising azithrocycin monohydrate
SI1480679T1 (sl) Farmacevtska formulacija Iressa, ki obsega vodotopen celulozni derivat
AU2002333896A1 (en) Solid pharmaceutical formulation for a piperazine urea derivative
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
IL174081A0 (en) Formulation for obtaining a pharmaceutical composition, methods of obtaining and use thereof
AU2003215543A1 (en) Water- soluble derivatives of lipophilic drugs
AU2003242538A1 (en) Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
HRP20040757A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed